Bristol Myers Squibb faces some challenges, but there could be light at the end of the tunnel for long-term investors.…
Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda…
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.…
Bristol-Myers Squibb stock slips despite earnings beat…
Bristol-Myers Squibb earnings beat by $0.07, revenue topped estimates…
Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio…
Jörg Reinhardt tritt nach zwölf Jahren als Novartis-Chef zurück. Sein Nachfolger steht bereits fest. Er kommt von einem direkten Konkurrenten.…
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative…
…
Bristol Myers Squibb and Cellares reach $380 million supply deal for CAR-T therapies…
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.…
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.…
The Global CAR T-Cell Therapy Market Size was Valued at USD 4.29 Billion in 2023 and the Worldwide CAR T-Cell…
Für viele Pharma- und Biotechaktionäre hat dieser Sektor einen ganz besonderen Charme. In dieser hochspekulativen Branche liegen Erfolg und Misserfolg…
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard…
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard…
The Global Chemotherapy Market Size was Valued at USD 8.6 Billion in 2023 and the Worldwide Chemotherapy Market Size is…
…
87 Prozent, 97 Prozent und 105 Prozent – diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…
87 Prozent, 97 Prozent und 105 Prozent - diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…
87 Prozent, 97 Prozent und 105 Prozent – diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…
…
NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
…
The company is going through a rough patch.…
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
…
Bristol Myers Squibb completes Karuna Therapeutics buyout…
…
Karuna Therapeutics set to merge with Bristol-Myers Squibb…
Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Bristol-Myers Squibb Company…
…
Der Global Anti Virus Health Net Return Index hat in den zurückliegenden Tagen von der Mehrheit der Indexmitglieder Rückenwind erhalten.…
Societe Generale cuts Bristol-Myers Squibb to Hold…
…
Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024" has…
…
…
…
The dynamics of the follicular lymphoma market are anticipated to change in the coming years owing to the improvement in…
Bristol Myers Squibb completes RayzeBio acquisition…
NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol-Myers Squibb will seinen Konkurrenten Karuna Therapeutics übernehmen. Die…
NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol Myers Squibb (BMS) kämpft weiter mit zunehmender Konkurrenz…